[go: up one dir, main page]

WO2008036196A3 - Indolylalkylpyridin-2-amines pour l'inhibition de la bêta-sécrétase - Google Patents

Indolylalkylpyridin-2-amines pour l'inhibition de la bêta-sécrétase Download PDF

Info

Publication number
WO2008036196A3
WO2008036196A3 PCT/US2007/019945 US2007019945W WO2008036196A3 WO 2008036196 A3 WO2008036196 A3 WO 2008036196A3 US 2007019945 W US2007019945 W US 2007019945W WO 2008036196 A3 WO2008036196 A3 WO 2008036196A3
Authority
WO
WIPO (PCT)
Prior art keywords
indolylalkylpyridin
secretase
amines
inhibition
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019945
Other languages
English (en)
Other versions
WO2008036196A2 (fr
Inventor
Yinfa Yan
Ping Zhou
Yi Fan
Albert Jean Robichaud
Michael Sotirios Malamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to EP07838193A priority Critical patent/EP2064201A2/fr
Priority to MX2009003102A priority patent/MX2009003102A/es
Priority to JP2009529195A priority patent/JP2010504326A/ja
Priority to CA002662348A priority patent/CA2662348A1/fr
Publication of WO2008036196A2 publication Critical patent/WO2008036196A2/fr
Publication of WO2008036196A3 publication Critical patent/WO2008036196A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé à base d'une indolylalkylpyridin-2-amine de formule (I). La présente invention concerne également ses procédés d'utilisation pour inhiber la ß-sécrétase (BACE) et traiter des dépôts de ß-amyloïde et des enchevêtrements neurofibrillaires.
PCT/US2007/019945 2006-09-21 2007-09-14 Indolylalkylpyridin-2-amines pour l'inhibition de la bêta-sécrétase Ceased WO2008036196A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07838193A EP2064201A2 (fr) 2006-09-21 2007-09-14 Indolylalkylpyridin-2-amines pour l'inhibition de la beta-secretase
MX2009003102A MX2009003102A (es) 2006-09-21 2007-09-14 INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
JP2009529195A JP2010504326A (ja) 2006-09-21 2007-09-14 β−セクレターゼを阻害するためのインドリルアルキルピリジン−２−アミン
CA002662348A CA2662348A1 (fr) 2006-09-21 2007-09-14 Indolylalkylpyridin-2-amines pour l'inhibition de la .beta.-secretase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84637306P 2006-09-21 2006-09-21
US60/846,373 2006-09-21

Publications (2)

Publication Number Publication Date
WO2008036196A2 WO2008036196A2 (fr) 2008-03-27
WO2008036196A3 true WO2008036196A3 (fr) 2008-05-29

Family

ID=39155214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019945 Ceased WO2008036196A2 (fr) 2006-09-21 2007-09-14 Indolylalkylpyridin-2-amines pour l'inhibition de la bêta-sécrétase

Country Status (6)

Country Link
US (1) US20080076801A1 (fr)
EP (1) EP2064201A2 (fr)
JP (1) JP2010504326A (fr)
CA (1) CA2662348A1 (fr)
MX (1) MX2009003102A (fr)
WO (1) WO2008036196A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE531720T1 (de) * 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
WO2008058402A1 (fr) * 2006-11-17 2008-05-22 Queen's University At Kingston Composés et procédés pour traiter des troubles de repliement de protéine
PE20090160A1 (es) * 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
CL2008000791A1 (es) * 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
US8404680B2 (en) * 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079687A1 (en) * 2004-08-06 2006-04-13 Ellen Baxter Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE)
WO2006083760A1 (fr) * 2005-02-01 2006-08-10 Wyeth Aminopyridines constituant des inhibiteurs de la $g(b)-secretase

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45198B1 (en) * 1976-06-05 1982-07-14 Wyeth John & Brother Ltd Guanidine derivatives
GB1588096A (en) * 1978-05-20 1981-04-15 Wyeth & Bros Ltd John Pyrrole derivatives
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
WO2003094854A2 (fr) * 2002-05-07 2003-11-20 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles et composes associes
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
PE20060459A1 (es) * 2004-06-16 2006-05-30 Wyeth Corp DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
DE602005012825D1 (de) * 2004-06-16 2009-04-02 Wyeth Corp Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
BRPI0606690A2 (pt) * 2005-01-14 2009-07-14 Wyeth Corp composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
WO2006088694A1 (fr) * 2005-02-14 2006-08-24 Wyeth THIÉNYL- ET FURYLACYLGUANIDINE SUBSTITUÉES ET MÉTHODES D'EMPLOI DESDITS COMPOSÉS EN TANT QUE RÉGULATEURS DE LA β-SECRÉTASE
MX2007009864A (es) * 2005-02-14 2007-09-04 Wyeth Corp Azolilacilguanidinas como inhibidores de (-secretasa.
WO2006088705A1 (fr) * 2005-02-14 2006-08-24 Wyeth Guanidine de terphenyle en tant qu'inhibiteurs de la $g(b)-secretase
CN101213183A (zh) * 2005-06-30 2008-07-02 惠氏公司 氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CN101273018A (zh) * 2005-09-26 2008-09-24 惠氏公司 用于β分泌酶（BACE）抑制剂的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑酮化合物
EP1966185A2 (fr) * 2005-12-19 2008-09-10 Wyeth a Corporation of the State of Delaware DÉRIVÉS DE 2-AMINO-5-PIPÉRIDINYLIMIDAZOLONE ET APPLICATIONS À LA MODULATION DE LA ß-SECRÉTASE
WO2007100536A1 (fr) * 2006-02-24 2007-09-07 Wyeth COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079687A1 (en) * 2004-08-06 2006-04-13 Ellen Baxter Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE)
WO2006083760A1 (fr) * 2005-02-01 2006-08-10 Wyeth Aminopyridines constituant des inhibiteurs de la $g(b)-secretase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY OF HETEROCYCLIC COMPOUNDS (NEW YORK, NY, UNITED STATES)(TRANSLATION OF KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII) , 36(11), 1347-1348 CODEN: CHCCAL; ISSN: 0009-3122, 2000 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAMSONIYA, SH. A. ET AL: "New derivatives of indole. Synthesis of photochromic 2-arylindole systems", XP002472908, retrieved from STN Database accession no. 2001:379955 *
ERWIN VON ANGERER, JOSEF STROHMEIER: "2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity", J. MED. CHEM., vol. 30, 1987, pages 131 - 136, XP002472907 *
KUMIKO TAKEUCHI, JOLIE A. BASTIAN, DONETTA S. GIFFORD-MOORE, RICHARD W. HARPER ET AL.: "1,2-Disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety. A novel series of thrombin inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 2347 - 2351, XP002472906 *

Also Published As

Publication number Publication date
CA2662348A1 (fr) 2008-03-27
EP2064201A2 (fr) 2009-06-03
MX2009003102A (es) 2009-04-01
US20080076801A1 (en) 2008-03-27
WO2008036196A2 (fr) 2008-03-27
JP2010504326A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2008118379A3 (fr) Composés amino-5-[4-(difluorométhoxy)phényl]-5-phénylimidazolone pour l'inhibition de la β-secrétase
MX2009009699A (es) Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa.
NO20074148L (no) Azolylacylguanidiner som beta-sekretase inhibitorer
WO2007078813A3 (fr) DÉRIVÉS DE 2-AMINO-5-PIPÉRIDINYLIMIDAZOLONE ET APPLICATIONS À LA MODULATION DE LA ß-SECRÉTASE
WO2008083252A3 (fr) Procédés d'utilisation pour des analogues de cyclopamine
WO2007016012A3 (fr) Composes de cycloalkyl amino-hydantoin et leur utilisation pour moduler la $g(b)-secretase
WO2008011560A3 (fr) Inhibiteurs de la rho kinase à base de benzothiophène
TW200640924A (en) VEGF-R2 inhibitors and methods
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
WO2008055068A8 (fr) Inhibiteurs de l'histone désacétylase
WO2008033836A3 (fr) Processus et intermédiaires destinés à préparer des inhibiteurs d'intégrase
WO2007085895A3 (fr) Inhibiteurs fap
TW200738683A (en) Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
WO2008064866A8 (fr) Traitement du myélome multiple
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
WO2010021934A3 (fr) Inhibiteurs azaindoles d’iap
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
WO2009156041A3 (fr) Dérivés de thiazolyl-piperidine
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2008036196A3 (fr) Indolylalkylpyridin-2-amines pour l'inhibition de la bêta-sécrétase
UA101018C2 (ru) Пирролопиримидинкарбоксамиды
MX2011006560A (es) Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2662348

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007838193

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009529195

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/003102

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838193

Country of ref document: EP

Kind code of ref document: A2